Literature DB >> 20410925

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.

J Boultwood1, J Perry, R Zaman, C Fernandez-Santamaria, T Littlewood, R Kusec, A Pellagatti, L Wang, R E Clark, J S Wainscoat.   

Abstract

We have undertaken a genome-wide single nucleotide polymorphism (SNP) array analysis of 41 chronic myeloid leukemia (CML) patients. In total, 44 regions of uniparental disomy (UPD) >3 Mb were identified in 24 of 32 patients in chronic phase (CP), and 21 regions of UPD >3 Mb were identified in 13 of 21 patients in blast crisis (BC). Chromosome 8 had the highest frequency of UPD regions in both CP and BC samples. Eight recurrent regions of UPD were observed among the 41 patients, with chromosome 8 showing the highest frequency. Ten regions of copy number change (CNC) >3 Mb were observed in 4 of 21 patients in BC, whereas none were observed in CP. We have identified several recurrent regions of UPD and CNC in CML that may be of pathogenetic importance. Overrepresentation of genomic aberrations (UPD and copy number gain) mapping to chromosome 8 was observed. Selected candidate genes mapping within the aberrant genomic regions were sequenced and mutation of the TP53 gene was observed in one case in BC and of the ASXL1 gene in 6 of 41 cases in CP or BC. Mutation of ASXL1 represents an important new molecular abnormality in CML.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410925     DOI: 10.1038/leu.2010.65

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  39 in total

Review 1.  Systematic review of pre-clinical chronic myeloid leukaemia.

Authors:  Jew Win Kuan; Anselm Ting Su; Chooi Fun Leong; Motomi Osato; Goro Sashida
Journal:  Int J Hematol       Date:  2018-09-14       Impact factor: 2.490

2.  Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak.

Authors:  Jew Win Kuan; Anselm Ting Su; Siow Phing Tay; Isabel Lim Fong; Sho Kubota; Lela Su'ut; Motomi Osato; Goro Sashida
Journal:  Int J Hematol       Date:  2019-11-09       Impact factor: 2.490

3.  The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.

Authors:  O Abdel-Wahab; O Kilpivaara; J Patel; L Busque; R L Levine
Journal:  Leukemia       Date:  2010-07-01       Impact factor: 11.528

Review 4.  Selection of therapy: rational decisions based on molecular events.

Authors:  Jamshid S Khorashad; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

Review 5.  Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Authors:  Susan Branford; Dennis Dong Hwan Kim; Jane F Apperley; Christopher A Eide; Satu Mustjoki; S Tiong Ong; Georgios Nteliopoulos; Thomas Ernst; Charles Chuah; Carlo Gambacorti-Passerini; Michael J Mauro; Brian J Druker; Dong-Wook Kim; Francois-Xavier Mahon; Jorge Cortes; Jerry P Radich; Andreas Hochhaus; Timothy P Hughes
Journal:  Leukemia       Date:  2019-06-17       Impact factor: 11.528

6.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Authors:  Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

7.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

8.  Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.

Authors:  Jiapeng Wang; Zhaomin Li; Yongzheng He; Feng Pan; Shi Chen; Steven Rhodes; Lihn Nguyen; Jin Yuan; Li Jiang; Xianlin Yang; Ophelia Weeks; Ziyue Liu; Jiehao Zhou; Hongyu Ni; Chen-Leng Cai; Mingjiang Xu; Feng-Chun Yang
Journal:  Blood       Date:  2013-11-19       Impact factor: 22.113

Review 9.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

10.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.

Authors:  Robert R West; Amy P Hsu; Steven M Holland; Jennifer Cuellar-Rodriguez; Dennis D Hickstein
Journal:  Haematologica       Date:  2013-09-27       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.